Changes in the transcriptome of circulating immune cells of a N Z cohort with ME/CFS

Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis/chronic fatigue syndrome, by Eiren Sweetman, Margaret Ryan, Christina Edgar, Angus MacKay, Rosamund Vallings, Warren Tate in International Journal of Immunopathology and Pharmacology vol 33 2019 [Published January 11, 2019]

 

Research abstract:
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a poorly understood disease affecting 0.2%–2% of the global population. To gain insight into the pathophysiology of ME/CFS in New Zealand, we examined the transcriptomes of peripheral blood mononuclear cells by RNA-seq analysis in a small well-characterized patient group (10 patients), with age/gender-matched healthy controls (10 control subjects).

Twenty-seven gene transcripts were increased 1.5- to sixfold and six decreased three- to sixfold in the patient group (P < 0.01). The top enhanced gene transcripts, IL8, NFΚBIA and TNFAIP3, are functionally related to inflammation, and significant changes were validated for IL8 and NFΚBIA by quantitative polymerase chain reaction (qPCR).

Functional network analysis of the altered gene transcripts (P < 0.01) detected interactions between the products related to inflammation, circadian clock function, metabolic dysregulation, cellular stress responses and mitochondrial function. Ingenuity pathway analysis (P < 0.05) provided further insights into the dysfunctional physiology, highlighting stress and inflammation pathways.

This analysis provides novel insights into the molecular changes in ME/CFS and contributes to the understanding of the pathophysiological mechanisms of the disease.

From the conclusion:

Our exploratory approach has enabled us to obtain a rich differentially expressed gene dataset to identify changed biology in ME/CFS. We have identified the circadian rhythm dysregulation pathway as a new possible underlying cause of the unrefreshing sleep, fatigue and metabolic abnormalities seen in ME/CFS. Furthermore, impaired mitochondrial function and resulting oxidative stress, coupled with chronic immune-inflammatory signalling, provides a compelling explanation for the fatigue, cognitive dysfunction and post-exertion malaise experienced in ME/CFS.

Therefore, this study is a further step towards gaining an understanding of the disease process and identifying putative biomarkers to support clinical diagnosis. The biological pathways identified offer a rational explanation of the complex and often multi-systemic nature of ME/CFS.

Posted in News | Tagged , , , , , , , , , , , , | Comments Off on Changes in the transcriptome of circulating immune cells of a N Z cohort with ME/CFS

A compromised paraventricular nucleus within a dysfunctional hypothalamus: A novel neuroinflammatory paradigm for ME/CFS

A compromised paraventricular nucleus within a dysfunctional hypothalamus: A novel neuroinflammatory paradigm for ME/CFS, by Angus Mackay, Warren P Tate in International Journal of Immunopathology and Pharmacology Vol: 32 [published online: December 6, 2018]

 

Article abstract: 
A neuroinflammatory paradigm is presented to help explain the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

The hypothalamic paraventricular nucleus (PVN) is responsible for absorbing and processing multiple, incoming and convergent ‘stress’ signals, and if this cluster of neurons were affected (by neuroinflammation), the ongoing hypersensitivity of ME/CFS patients to a wide range of ‘stressors’ could be explained.

Neuroinflammation that was chronic and fluctuating, as ‘inflammatory-marker’ studies support, could reflect a dynamic change in the hypothalamic PVN’s threshold for managing incoming ‘stress’ signals. This may not only be a mechanism underpinning the characteristic feature of ME/CFS, post-exertional malaise, and its associated debilitating relapses, but could also be responsible for mediating the long-term perpetuation of the disease.

Triggers (sustained physiological ‘stressors’) of ME/CFS, such as a particular viral infection, toxin exposure, or a traumatic event, could also target the hypothalamic PVN, a potentially vulnerable site in the brains of ME/CFS susceptible people, and disruption of its complex neural circuitry could account for the onset of ME/CFS.

In common with the different ‘endogenous factors’ identified in the early ‘neuroinflammatory’ stages of the ‘neurodegenerative’ diseases, an as yet, unidentified factor within the brains and central nervous system (CNS) of ME/CFS patients might induce both an initial and then sustained ‘neuroinflammatory’ response by its ‘innate immune system’.  Positron emission tomography/magnetic resonance imaging has reinforced evidence of glial cell activation centred on the brain’s limbic system of ME/CFS patients.

Neuroinflammation causing dysfunction of the limbic system and its hypothalamus together with a consequently disrupted autonomic nervous system could account for the diverse range of symptoms in ME/CFS relating, in particular to fatigue, mood, cognitive function, sleep, thermostatic control, gastrointestinal disturbance, and hypotension.

Posted in News | Tagged , , , , , | Comments Off on A compromised paraventricular nucleus within a dysfunctional hypothalamus: A novel neuroinflammatory paradigm for ME/CFS

Estimating prevalence, demographics & costs of ME/CFS using large scale medical claims data & Machine Learning (US)

Estimating prevalence, demographics and costs of ME/CFS using large scale medical claims data and machine learning, by Ashley Valdez, Elizabeth E. Hancock, Seyi Adebayo, David Kiernicki, Daniel Proskauer, John R. Attewell, Lucinda Bateman, Alfred DeMaria, Jr, Charles W. Lapp, Peter C. Rowe and Charmian Proskauer in Front. Pediatr. 08 January 2019

Research abstract:
Techniques of data mining and machine learning were applied to a large database of medical and facility claims from commercially insured patients to determine the prevalence, gender demographics, and costs for individuals with provider-assigned diagnosis codes for myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS).

The frequency of diagnosis was 519 – 1,038/100,000 with the relative risk of females being diagnosed with ME or CFS compared to males 1.238 and 1.178, respectively. While the percentage of women diagnosed with ME/CFS is higher than the percentage of men, ME/CFS is not a “woman’s disease.” Thirty-five to forty percent of diagnosed patients are men.

Extrapolating from this frequency of diagnosis and based on the estimated 2017 population of the United States, a rough estimate for the number of patients who may be diagnosed with ME or CFS in the U.S. is 1.7 million to 3.38 million.

Patients diagnosed with CFS appear to represent a more heterogeneous group than those diagnosed with ME. A machine learning model based on characteristics of individuals diagnosed with ME was developed and applied, resulting in a predicted prevalence of 857/100,000 (p>0.01), or roughly 2.8 million in the U.S.

Average annual costs for individuals with a diagnosis of ME or CFS were compared with those for lupus (all categories) and multiple sclerosis (MS), and found to be 50% higher for ME and CFS than for lupus or MS, and three to four times higher than for the general insured population.

A separate aspect of the study attempted to determine if a diagnosis of ME or CFS could be predicted based on symptom codes in the insurance claims records. Due to the absence of specific codes for some core symptoms, we were unable to validate that the information in insurance claims records is sufficient to identify diagnosed patients or suggest that a diagnosis of ME or CFS should be considered based solely on looking for presence of those symptoms.

These results show that a prevalence rate of 857/100,000 for ME/CFS is not unreasonable; therefore, it is not a rare disease, but in fact a relatively common one.

Posted in News | Tagged , , , , , , , , , , , , , , , | Comments Off on Estimating prevalence, demographics & costs of ME/CFS using large scale medical claims data & Machine Learning (US)

Initiating care of a patient with ME/CFS

Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), by Charles W. Lapp in Front. Pediatr., [Published 23 January 2019]

 

Article abstract:
This paper introduces the primary care physician to the unique and challenging aspects of initially diagnosing and managing a complex condition for which there are a plethora of symptoms, few physical findings, no known cause, and no specific treatments. While daunting, the rewards are many, and those who pursue an interest in ME/CFS find themselves at the forefront of medicine.

The approach to any complex problem is to break it down into small steps, and ME/CFS is no exception. The first office visit should be devoted to a history of the present illness, a physical examination, and collection of exclusionary laboratory tests. On follow-up the differential diagnosis and a treatment plan can be addressed. Many individuals with ME/CFS have been humiliated or dismissed by other providers, so one will need to be as non-judgmental as possible and acknowledge that ME/CFS is not a psychological condition but a real illness. They need reassurance that you will work with them to seek a unifying diagnosis and prioritize management.

Management

Many patients will be seeking rapid relief and even a cure for their illness, but foremost they must have realistic expectations: ME/CFS is a chronic illness for which there is currently no known cure. Nevertheless, there are many treatments that can be helpful to reduce symptoms and improve functionality.

Most experts would agree (9) that it is most important to address exertion intolerance and post-exertional malaise first; then sleep and pain, followed by cognition and the co-morbidities. Experts will agree that patients must avoid over-exerting and then flaring or relapsing—referred to as “pushing and crashing”—which clearly exacerbates the illness and hinders improvement. The controversy surrounds how to best prevent that.

One technique is interval activity or time-based activity. If an individual knows that they can be active for a period of time without triggering symptoms—say 15 min—then he or she can shop or work for 15 min, take a break, then shop or work for another 15 min, and so on. Over time, the activity interval can be increased (10).

Another technique is to monitor steps per day by wearing a step meter or pedometer (11). It is important for patients to take at least 1,000 steps per day in order to avoid deconditioning; but patients are encouraged to calculate their average steps per day during a good week with no flares or relapses. This is typically about 2,500–3,500 steps per day. They are then encouraged to not exceed that number of steps. So if a patient went shopping or sightseeing one day and reached her average limit of 3,500 steps, she would know to quit and rest as soon as possible to avoid a flare or relapse.

Scientific evidence is mounting that patients should not exceed their Anaerobic Threshold, an activity level at which the heart and lungs cannot supply enough oxygen to the mitochondria. In the absence of oxygen, glucose metabolism is much less efficient and produces lactic acid and other toxins that seem detrimental to our patients. The Anaerobic Threshold is usually determined by specialized exercise testing, but is related to one’s heart rate. So if a patient can monitor heart rate, he or she can estimate the maximum heart rate (frequently under 110 in adults) that can be tolerated without triggering a flare. Then avoid exceeding that heart rate except for short periods (12).

In short, it is very important to balance any activity with generous amounts of rest. So the patient should be encouraged to remain active, but not so active as to trigger flares and relapses.

Sleep is the next most important area to address. Start with typical sleep hygiene principles. Patients may consider over-the-counter sleep aids such as melatonin, theanine, valerian, tryptophan, antihistamines (diphenhydramine, doxylamine), or proprietary sleep aids. Low dose tricyclic or tetracyclic antidepressants, cyclobenzaprine, or low dose tizanidine are frequently prescribed to maintain sleep. If necessary, consider prescribing the usual benzodiazepine -based sleep medications to initiate sleep. Between 18 and 62% of persons with ME/CFS have primary sleep disorders, so highly consider referral to a sleep specialist if a sleep disorder is suspected (13).

Pain is another major symptom to address as it may affect sleep, mood, mobility and other domains. First identify the sources of pain: Fibromyalgia? Myofascial pain? Headache? Arthralgia? Inflammatory joint pain? Then assess the patient’s need for pain intervention. Will non-pharmacologic therapy suffice such as hot packs, cold packs, liniments, baths or showers, massage, chiropractic, acupuncture, or TENS? If pharmacologic therapy is indicated, have non-opioid therapies been tried such as Cymbalta/duloxetine, Savella/milnacipran, or Lyrica/pregabalin? (7) In the last 10 years Low Dose Naltrexone has become a primary consideration in opioid-naïve individuals (14). If opioid medications are indicated, tramadol has been very effective, but many providers would be most comfortable referring to a pain specialist for anything more potent. In the case of migraine or rheumatic pain, specialists might also be indicated.

Cognitive problems tend to wax and wane, much as fatigue does. Patients need to be reassured that they are not developing Alzheimer’s or dementia, and there is no evidence that such cognitive losses are permanent. While medication has helped little to improve cognition, the provider can suggest helpful techniques such as:

  • Keep a calendar, notebook and calculator at hand.
  • Always carry a cell phone to call for assistance, use as a GPS, or photograph your location in a parking lot or unfamiliar area.
  • Develop the habit of always putting up important items such as keys, purses, wallets, and glasses in the same place.
  • Plan important tasks to be done during the “best time of your day.”
  • Avoid chaotic, stressful, or multisensory situations or events.

Autonomic, (auto)immune, (neuro)endocrine, psychological and co-morbid issues are managed as you would normally in your medical practice. It is imperative to address co-morbidities because they confound the ME/CFS. Consultants may be required. It is very important not to attribute all new symptoms to ME/CFS alone. Lastly, patients must maintain adequate hydration and nutrition although they tend to neglect these areas due to fatigue.

Posted in News | Tagged , , , , , , , | Comments Off on Initiating care of a patient with ME/CFS

Neuroinflammation & cytokines in ME/CFS: a critical review of research methods

Neuroinflammation and  cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a critical review of research methods, by Michael B VanElzakker, Sydney A. Brumfield and Paula S. Lara Mejia in Front. Neurol., 10 January 2019

Review article abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is the label given to a syndrome that can include long-term flu-like symptoms, profound fatigue, trouble concentrating, and autonomic problems, all of which worsen after exertion. It is unclear how many individuals with this diagnosis are suffering from the same condition or have the same underlying pathophysiology, and the discovery of biomarkers would be clarifying.

The name “myalgic encephalomyelitis” essentially means “muscle pain related to central nervous system inflammation” and many efforts to find diagnostic biomarkers have focused on one or more aspects of neuroinflammation, from periphery to brain. As the field uncovers the relationship between the symptoms of this condition and neuroinflammation, attention must be paid to the biological mechanisms of neuroinflammation and issues with its potential measurement.

The current review focuses on three methods used to study putative neuroinflammation in ME/CFS:

  1. positron emission tomography (PET) neuroimaging using translocator protein (TSPO) binding radioligand
  2. magnetic resonance spectroscopy (MRS) neuroimaging and
  3. assays of cytokines circulating in blood and cerebrospinal fluid.

PET scanning using TSPO-binding radioligand is a promising option for studies of neuroinflammation. However, methodological difficulties that exist both in this particular technique and across the ME/CFS neuroimaging literature must be addressed for any results to be interpretable.

We argue that the vast majority of ME/CFS neuroimaging has failed to use optimal techniques for studying brainstem, despite its probable centrality to any neuroinflammatory causes or autonomic effects.

MRS is discussed as a less informative but more widely available, less invasive, and less expensive option for imaging neuroinflammation, and existing studies using MRS neuroimaging are reviewed.

Studies seeking to find a peripheral circulating cytokine “profile” for ME/CFS are reviewed, with attention paid to the biological and methodological reasons for lack of replication among these studies. We argue that both the biological mechanisms of cytokines and the innumerable sources of potential variance in their measurement make it unlikely that a consistent and replicable diagnostic cytokine profile will ever be discovered.

 

#MEAction: Neuroinflammation review by #MEAction research fellows

 

Posted in News | Tagged , , , , , | Comments Off on Neuroinflammation & cytokines in ME/CFS: a critical review of research methods

The importance of accurate diagnosis of ME/CFS in children & adolescents: a commentary

The importance of accurate diagnosis of ME/CFS in children and adolescents: a commentary, by Keith J Geraghty and Charles Adeniji in Frontiers in Pediatrics [Preprint December 31, 2018]

Article abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic illness that causes a range of debilitating symptoms. While most research has focused on adults, the illness also presents in children and adolescents. Many physicians find it difficult to diagnose the illness.

In this commentary paper, we discuss a range of salient themes that have emerged from our ongoing research into the prevalence of ME/CFS in children and adolescents. We discuss reasons why paediatric prevalence estimates vary widely in the literature, from almost 0% to as high as 3%.

We argue that there is considerable misdiagnosis of paediatric cases and over-inflation of estimates of paediatric ME/CFS. Many children and teenagers with general fatigue and other medical complaints may meet loose diagnostic criteria for ME/CFS.

We make recommendations for improving epidemiological research and identifying
paediatric ME/CFS in clinical practice.

 

Posted in News | Tagged , , , , , , , | Comments Off on The importance of accurate diagnosis of ME/CFS in children & adolescents: a commentary

CFS in the emergency department (US)

Chronic fatigue syndrome in the emergency department, by CR Timbol, JN Baraniuk in Open Access Emergency Medicine Vol 11, pp 15-28, [Published 11 January 2019]

 

Research abstract:

Purpose:
Chronic fatigue syndrome (CFS) is a debilitating disease characterized by fatigue, postexertional malaise, cognitive dysfunction, sleep disturbances, and widespread pain. A pilot, online survey was used to determine the common presentations of CFS patients in the emergency department (ED) and attitudes about their encounters.

Methods:
The anonymous survey was created to score the severity of core CFS symptoms, reasons for going to the ED, and Likert scales to grade attitudes and impressions of care. Open text fields were qualitatively categorized to determine common themes about encounters.

Results:

Fifty-nine percent of respondents with physician-diagnosed CFS (total n=282) had gone to an ED. One-third of ED presentations were consistent with orthostatic intolerance; 42% of participants were dismissed as having psychosomatic complaints. ED staff were not knowledgeable about CFS. Encounters were unfavorable (3.6 on 10-point scale). The remaining 41% of subjects did not go to ED, stating nothing could be done or they would not be taken seriously. CFS subjects can beidentified by a CFS questionnaire and the prolonged presence (>6 months) of unremitting fatigue, cognitive, sleep, and postexertional malaise problems.

Conclusion:
This is the first investigation of the presentation of CFS in the ED and indicates the importance of orthostatic intolerance as the most frequent acute cause for a visit. The self-report CFS questionnaire may be useful as a screening instrument in the ED. Education of ED staff about modern concepts of CFS is necessary to improve patient and staff satisfaction. Guidance is provided for the diagnosis and treatment of CFS in these
challenging encounters.

In the media:

Daily Mail:  ‘It’s all in your head’: Half of patients with chronic fatigue
syndrome claim they are dismissed by doctors who say the
illness is psychological

Georgetown University press release: Perceptions of chronic fatigue syndrome in the emergency department

 

Posted in News | Tagged , , , , , , | Comments Off on CFS in the emergency department (US)

Genome-epigenome interactions associated with ME/CFS

Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by Santiago Herrera, Wilfred C de Vega, David Ashbrook, Suzanne D Vernon and Patrick O McGowan in Epigenetics 2018 [Published online: 5 Dec 2018]

 

Research abstract:

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex disease of unknown etiology. Multiple studies point to disruptions in immune functioning in ME/CFS patients as well as specific genetic polymorphisms and alterations of the DNA methylome in lymphocytes.

However, potential interactions between DNA methylation and genetic background in relation to ME/CFS have not been examined. In this study we explored this association by characterizing the epigenetic (~480 thousand CpG loci) and genetic (~4.3 million SNPs) variation between cohorts of ME/CFS patients and healthy controls. We found significant associations of DNA methylation states in T-lymphocytes at several CpG loci and regions with ME/CFS phenotype. These methylation anomalies are in close proximity to genes involved with immune function and cellular metabolism. Finally, we found significant correlations of genotypes with methylation modifications associated with ME/CFS.

The findings from this study highlight the role of epigenetic and genetic interactions in complex diseases, and suggest several genetic and epigenetic elements potentially involved in the mechanisms of disease in ME/CFS.

Read full paper

Posted in News | Tagged , , , , , , , | Comments Off on Genome-epigenome interactions associated with ME/CFS

Prospective biomarkers from plasma metabolomics of ME/CFS implicate redox imbalance in disease symptomatology

Prospective biomarkers from plasma metabolomics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome implicate Redox imbalance in disease symptomatology, by Arnaud Germain, David Ruppert, Susan M. Levine and Maureen R. Hanson in Metabolites 2018, 8(4), 90 [Published 6 Dec 2018]

 

Research abstract:
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease of enigmatic origin with no established cure. Its constellation of symptoms has silently ruined the lives of millions of people around the world. A plethora of hypotheses have been vainly investigated over the past few decades, so that the biological basis of this debilitating condition remains a mystery.

In this study, we investigate whether there is a disturbance in homeostasis of metabolic networks in the plasma of a female 32-patient cohort compared to 19 healthy female controls.

Extensive analysis of the 832-metabolite dataset generated by Metabolon®, covering eight biological classes, generated important insight into metabolic disruptions that occur in ME/CFS. We report on 14 metabolites with differences in abundance, allowing us to develop a theory of broad redox imbalance in ME/CFS patients, which is consistent with findings of prior work in the ME/CFS field.

Moreover, exploration of enrichment analysis using www.MetaboAnalyst.ca provides information concerning similarities between metabolite disruptions in ME/CFS and those that occur in other diseases, while its biomarker analysis unit yielded prospective plasma biomarkers for ME/CFS. This work contributes key elements to the development of ME/CFS diagnostics, a crucial step required for discovering a therapy for any disease of unknown origin.

Comment: Metabolomics Study Suggests Chronic Fatigue Syndrome May Be Oxidative Stress/Low Oxygen Disease

 

 

Posted in News | Tagged , , , , , , | Comments Off on Prospective biomarkers from plasma metabolomics of ME/CFS implicate redox imbalance in disease symptomatology

Implementing guided ICBT for chronic pain & fatigue

Implementing guided ICBT for chronic pain and fatigue: A qualitative evaluation among therapists and managers by p in Internet Interventions
Volume 18, December 2019 [doi.org/10.1016/j.invent.2019.100290]

Highlights

  • ICBT for chronic somatic conditions such as pain and fatigue can overcome current barriers to provide patients with evidence-based psychological care
  • Implementing ICBT in mental health care has been found to be challenging on many levels
  • This study uses the Consolidated Framework for Implementation Research to evaluate an implementation project on ICBT for chronic pain and fatigue
  • Therapists and managers were interviewed and provided an extensive overview of key facilitating and hindering factors to adopt ICBT in daily clinical practice
  • Some key factors are “find support from all stakeholders”, “Align goals, expectations and skills”, and “create a feeling of ownership”.

 

Research abstract:

Introduction:
Internet-based cognitive behavioural therapy (ICBT) for chronic pain and chronic fatigue syndrome (CFS) has a high potential to increase the number of patients who can receive an evidence based treatment aimed to reduce symptoms and/or disability and to lower burden on (mental) health care. However, implementing a new behaviour-change intervention, and especially an online intervention, has shown to be a challenge. This study aimed to identify factors influencing the implementation process of ICBT for chronic pain and CFS in mental health care.

Methods
A qualitative study using semi-structured interviews with therapists and managers from twelve mental health care clinics was conducted. Questions and analysis were guided by the Consolidated Framework for Implementation Research (CFIR), covering five domains: (1) the implemented intervention, (2) individual characteristics of the users, (3) the inner setting of implementation, (4) the outer setting, and (5) the implementation process.

Results
In all five domains important facilitators and barriers were found. Key themes were: (1) the quality of the content, its perceived effectiveness and usability, (2) the attitude, self-efficacy and ability to learn new skills among therapists, and motivation to start online treatment among patients, (3) internal communication within a team, existing workload, and top-down support from the management, (4) availability of reimbursement options and marketing strategies, and (5) involvement of all key stakeholders, steering towards independence of the implementation sites during the process and adequate training of therapists.

Conclusions
This study provides insight in the challenge of implementing ICBT for chronic pain and CFS in daily clinical practice. Several lessons can be learned from the interviews with therapists and managers which can also be more broadly applied to (ICBT) implementation projects in general. Development of practical tools to support the implementation process would be a valuable next step to overcome certain challenges at forehand and to properly prepare for those expected to come along.

Posted in News | Tagged , , , , , , , , | Comments Off on Implementing guided ICBT for chronic pain & fatigue